Stay updated on Tagraxofusp in Secondary AML Clinical Trial
Sign up to get notified when there's something new on the Tagraxofusp in Secondary AML Clinical Trial page.

Latest updates to the Tagraxofusp in Secondary AML Clinical Trial page
- Check5 days agoChange DetectedAdded Revision: v3.4.3 to the record history and removed Revision: v3.4.2 from the history.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2 to the history page. The prior notices about government funding and operating status (v3.4.1) were removed.SummaryDifference0.6%

- Check41 days agoChange DetectedA government funding notice banner was added. The site revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.6%

- Check48 days agoChange DetectedThe history page now displays a glossary toggle and color-coded highlights for additions and deletions, along with revision details (v3.4.0) and No FEAR Act data notes.SummaryDifference1%

- Check62 days agoChange DetectedFooter revision label updated from v3.3.3 to v3.3.4. No study data or functionality were affected.SummaryDifference0.1%

- Check69 days agoChange DetectedThe TAGALONG trial record was updated to correct the study name from Azaxitadine to Azacitidine. The Study Status and Study Identification sections were added/updated with entries dated 2025-12-29 and 2025-12-31.SummaryDifference0.5%

Stay in the know with updates to Tagraxofusp in Secondary AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tagraxofusp in Secondary AML Clinical Trial page.